Axial Spondyloarthritis Treatment Market Report

Spondyloarthritis is a class of chronic autoimmune inflammatory diseases that share common genetic and clinical features. Axial spondyloarthritis is one of these diseases that predominantly affects the axial skeleton, especially the spine and sacroiliac joints. Some of the major symptoms of axial spondyloarthritis could be dealt with the use of non-steroidal anti-inflammatory drugs (NSAIDs). These drugs could carry disease-modifying properties such as delaying the structural damage of the spine. Apart from NSAIDs, tumor necrosis factor (TNF) α blockers are approved and considered effective to treat active axial spondyloarthritis. Besides these, there are a number of new drugs currently under investigation.

Drug manufacturers are launching new products in the global axial spondyloarthritis treatment market to gain growth and strengthen their customer base. In April 2019, Eli Lilly and Company, a US-based global pharmaceutical company, announced that its monoclonal antibody Taltz (ixekizumab) has cleared the phase 3 study COAST-X. This study evaluated Taltz’s efficacy and safety when used to treat non-radiographic axial spondyloarthritis.

Market Dynamics

The demand for axial spondyloarthritis treatment is anticipated to increase as there are a large number of patients with the disease across the world. As mentioned on the Johns Hopkins Arthritis Center’s website, approximately 0.2-0.5% of the US population is affected by ankylosing spondylitis. While non-radiographic axial spondyloarthritis is more common in females, ankylosing spondylitis occurs more frequently in male adults. Axial spondyloarthritis could usually include a series of extra-articular manifestations and co-morbidities, which includes uveitis, inflammatory bowel disease, and cardiovascular risk.

With the increase in the incidence of axial spondyloarthritis, there has been a rise in the number of approved biosimilar drugs. This is predicted to push the growth of the global axial spondyloarthritis treatment market. However, the expensive cost of biologics is foretold to delay the rise of the global market. Biologics could be expensive due to the requirement of high research and development investment and time-consuming manufacturing and testing procedures.

Market Segmentation

By Type

●   Ankylosing Spondylitis

●   Non-radiographic Axial Spondyloarthritis

Among type segments, ankylosing spondylitis is expected to show significant growth in the global axial spondyloarthritis treatment market. It is a type of arthritis where the inflammation of spinal joints is involved, which could cause chronic or severe discomfort and pain. Although it mainly affects the spine, other joints could also be affected because of the disease.

By Region

According to analysts, North America is prognosticated to achieve a remarkable share of the global axial spondyloarthritis treatment market due to favorable reimbursement scenarios, higher amount of income spent on healthcare compared to other regions, and increased awareness about the disease. Asia Pacific is foreseen to show quicker growth in the global market because of the improvement in healthcare infrastructure, large population, and increase in the number of geriatrics.

Key Players

The research study covers top players of the global axial spondyloarthritis treatment market such as UCB Biosciences GmbH, Pfizer, Abbott Pharmaceuticals, Merck Sharp & Dohme Corp., and GlaxoSmithKline plc. Each player is carefully assessed in the report with key focus on their market share, recent developments, production, revenue, and other vital factors.

Research Methodology

The findings presented in this report on the global axial spondyloarthritis treatment market are based on proven assumptions and research methodologies. QY Research is an expert in providing verifiable market projections, historical data, and qualitative and quantitative insights. The research study is prepared with the help of primary and secondary research processes that include key observations of experienced analysts, surveys, personal interviews with industry experts, government databases, trade journals, and recognized paid sources. Readers are offered with a separate analysis on industry regulations and mandates, microeconomic and macroeconomic factors, and the parent market.

Reasons to Buy this Report

●   For exclusive data on the global axial spondyloarthritis treatment market provided in QY Research’s latest research report

●   For authentic forecasts pertaining to capacity, production, value, consumption, growth rate (CAGR), market share, and milestones so far

●   For a valuable insights into manufacturers, capacity, production, revenue, market share, and recent developments

●   For identifying significant trends, drivers, global influence factors, and regions

Life sciences is a wide branch of study that is gradually becoming an integral industry to the global economics. QYR Consulting looks at the steady transformation of the life sciences industry and its impact on the subindustries such as medical care, pharmaceutical, and medical devices. Our team of esteemed analysts have put together reports to analyze the monumental changes life sciences is expected to bring in the overall healthcare industry. These reports identify the exact turning points for the industry and open up a platform for discussing its growth.

QYR Consulting brings to you a structured analysis of the technological advancements so far, vision of the players in the industry, and the strategies they are likely to use to make their mark. The reports dissect various components of the life sciences industry to scrutinize the influential factors. To help the readers make profitable business decisions, analysts have highlighted the lucrative investment areas and upcoming business opportunities.